General Notices

• Notice of Changes in NCI K00 Salary Caps in The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00)
  (NOT-CA-20-049)
  National Cancer Institute
  

• Notice of Information: Contributing to the Global COVID-19 Crisis Response by Allowing Some NCI-supported Projects to be Redirected to COVID-19-related Research During the Crisis
  (NOT-CA-20-054)
  National Cancer Institute
  

• Notice of a Joint Veterans Health Administration/National Cancer Institute Data Science Postdoctoral Fellowship - the Big Data Scientist Training Enhancement Program (BD-STEP)
  (NOT-CA-20-058)
  National Cancer Institute
  

• Pre-Application Webinar for RFA-CA-20-030, Utilizing Cohort Studies to Address Health Outcomes in Cancer Survivors (UG3/UH3 Clinical Trial Not Allowed)
  (NOT-CA-20-059)
  National Cancer Institute
  

• Pre-Application Webinar for RFA-HG-20-001 and RFA-HG-20-002, Polygenic Risk Score (PRS) Methods and Analysis for Populations of Diverse Ancestry Study Sites and Coordinating Center (U01 Clinical Trial Not Allowed)
  (NOT-HG-20-038)
  National Human Genome Research Institute
  

• The National Institutes of Health (NIH) Sexual & Gender Minority Research Office (SGMRO) Announces Webinar on Navigating the NIH for Researchers Interested in DSD and Intersex Populations
  (NOT-OD-20-102)
  Office of the Director, NIH
  

• Request for Information: Soliciting Input for the National Center for Complementary and Integrative Healths New Strategic Plan
  (NOT-AT-20-013)
  National Center for Complementary and Integrative Health
  

• Request for Information (RFI): Guidance on Current Clinical Experience in Suicide Prevention in Primary Care Settings
  (NOT-MH-20-046)
  National Institute of Mental Health
  

Notice of Changes to Funding Opportunities

• Notice to Extend the Expiration Date for PAR-17-170 "Alcohol Research Resource Awards (R24)"
  (NOT-AA-20-012)
  National Institute on Alcohol Abuse and Alcoholism
  

• Notice of Change to PAR-18-538 "Basic and Translation Research on Decision Making in Aging and Alzheimer's Disease (R21 - Clinical Trial Optional)"
  (NOT-AG-20-029)
  National Institute on Aging
  

• Notice of Change to PAR-18-544 "Basic and Translational Research on Decision Making in Aging and Alzheimer's Disease (R01 - Clinical Trial Optional)"
  (NOT-AG-20-030)
  National Institute on Aging
  

• Notice of Clarification to Eligibility Information in RFA- AI-20-029 Clinical Trials in Organ Transplantation in Children and Adults (CTOT-CA) (U01 Clinical Trial Optional)
  (NOT-AI-20-045)
  National Institute of Allergy and Infectious Diseases
  

• Notice of Change in Key Dates for RFA-AI-20-008 , Multidisciplinary Studies to Improve Understanding of Influenza Transmission (U19 Clinical Trial Optional)
  (NOT-AI-20-046)
  National Institute of Allergy and Infectious Diseases
  

• Notice of Change to the Receipt Date of PAR-17-496 and PAR-17-464, "Intervention Research to Improve Native American Health (R01/R21 Clinical Trial Optional)"
  (NOT-CA-20-053)
  National Cancer Institute
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute of Environmental Health Sciences
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  National Institute of Nursing Research
  

• Notice of Change to Application Due Date for RFA-CA-19-045 "Participant Engagement and Cancer Genome Sequencing (PE-CGS) (U2C Clinical Trial Optional)"
  (NOT-CA-20-056)
  National Cancer Institute
  

• Notice of Change to the First Receipt Date of RFA-CA-20-027 and RFA-CA-20-028, "Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R01/R21 Clinical Trial Optional)"
  (NOT-CA-20-057)
  National Cancer Institute
  

• Notice of An Additional Cycle of Receipt Dates Added to RFA-DA-20-028 Implementing the HIV Service Cascade for Justice-Involved Populations (U01 Clinical Trial Required)"
  (NOT-DA-20-051)
  National Institute on Drug Abuse
  

• Notice of Additional Activity Code Accepted for "NOT-DK-20-018, Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIDDK"
  (NOT-DK-20-026)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Notice of Correction to NOT-EY-20-005: Notice of NEI Participation in PAR-19-091 "NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)"
  (NOT-EY-20-007)
  National Eye Institute
  

• Notice of Correction to NOT-EY-20-006: NEI Participation in PAR-19-092 "NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)"
  (NOT-EY-20-008)
  National Eye Institute
  

• Notice to Extend Application Due Date for RFA-FD-20-027 "Integrated Pathogen Reduction Technologies for whole blood and blood components for transfusion (R01) Clinical Trial Not Allowed"
  (NOT-FD-20-026)
  Food and Drug Administration
  

• Notice of Change in Application Due Date for RFA-HL-21-011, Stimulating T4 Implementation Research to Optimize Integration of Proven-effective Interventions for HLB Diseases and Sleep Disorders into Practice (STIMULATE-2) (R61/R33 Clinical Trial Required)
  (NOT-HL-20-783)
  National Heart, Lung, and Blood Institute
  

• Notice of Change to the Award Project Period for PAR-19-197 "Summer Research Education Experience Program (R25 Clinical Trial Not Allowed)"
  (NOT-NS-20-050)
  National Institute of Neurological Disorders and Stroke
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Biomedical Imaging and Bioengineering
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences
  

• Notice of Extension of Expiration Date for PAR-17-456 "CREATE Bio Optimization Track for Biologics (U01 Clinical Trial Not Allowed)"
  (NOT-NS-20-053)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Extension of Expiration Date for PAR-17-457 "CREATE Bio Optimization Track for Biologics (SBIR) (U44 Clinical Trial Not Allowed)"
  (NOT-NS-20-054)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Extension of Expiration Date for PAR-18-542 "CREATE Bio Development Track: Nonclinical and Early-Phase Clinical Development for Biologics (U01 Clinical Trial Optional)"
  (NOT-NS-20-055)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Extension of Expiration Date for PAR-18-543 "CREATE Bio Development Track: Nonclinical and Early-Phase Clinical Development for Biologics (U44 Clinical Trial Optional)"
  (NOT-NS-20-056)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Change to Key Dates for PAR-19-211 "NINDS Institutional Research Training Program (T32)"
  (NOT-NS-20-059)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Change to Key Dates for PAR-19-228 "Institutional Translational Research Training Program (T32)"
  (NOT-NS-20-060)
  National Institute of Neurological Disorders and Stroke
  National Institute on Aging
  

• Notice of Change to Key Dates for PAR-20-076 "Jointly Sponsored Ruth L. Kirschstein National Research Service Award Institutional Predoctoral Training Program in the Neurosciences (T32 Clinical Trial Not Allowed)"
  (NOT-NS-20-061)
  National Institute of Neurological Disorders and Stroke
  National Institute on Aging
  National Institute on Drug Abuse
  National Institute of General Medical Sciences
  National Institute of Mental Health
  

• Notice of Correction to Key Dates for RFA-NS-20-029 "BRAIN Initiative: Exploratory Team-Research BRAIN Circuit Programs - eTeamBCP (U01 Clinical Trials Optional)"
  (NOT-NS-20-063)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Change to Key Dates for PAR-18-469 "NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity in Neuroscience Research (K22-No Independent Clinical Trials)"
  (NOT-NS-20-065)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Change in Eligibility and Activity Codes for NOT-TR-20-011, Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need
  (NOT-TR-20-018)
  National Center for Advancing Translational Sciences
  

• Notice to Extend the Expiration Date for PAR-17-465 "Bench Testing Therapeutic/Indication Pairing Strategies (UG3/UH3)"
  (NOT-TR-20-025)
  National Center for Advancing Translational Sciences
  

• Notice to Extend the Expiration Date for PAR-18-332 "Clinic Testing Therapeutic/Indication Pairing Strategies (U01 Clinical Trial Required)"
  (NOT-TR-20-026)
  National Center for Advancing Translational Sciences
  

• Notice to Extend the Expiration Date for PAR-18-462 "Clinical Trial Planning: Therapeutic/Indication Pairing Strategies (U34) (Clinical Trial Not Allowed)"
  (NOT-TR-20-027)
  National Center for Advancing Translational Sciences
  

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for NINDS Morris K. Udall Centers of Excellence for Parkinson's Disease Research (P50 Clinical Trial Optional)
  (NOT-NS-20-057)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Intent to Publish a Funding Opportunity Announcement for NINDS Exploratory Grant Program in Parkinson's Disease Research (P20- Clinical Trial Optional) (P20 Clinical Trial Optional)
  (NOT-NS-20-058)
  National Institute of Neurological Disorders and Stroke
  

Notices of Special Interest

• Notice of Special Interest (NOSI): Administrative Supplement to a Cancer Moonshot Coordinating Center (U24) to Support the Mechanisms of Cancer Drug Resistance and Sensitivity Network (DSRN)
  (NOT-CA-20-052)
  National Cancer Institute
  

• Notice of Special Interest (NOSI): Implementation of Clinical Care Guidelines on Opioid Prescribing for Pain Management
  (NOT-DA-20-038)
  National Institute on Drug Abuse
  National Center for Complementary and Integrative Health
  Office of Behavioral and Social Sciences Research
  

• Notice of Special Interest (NOSI): Infrastructure Access for Research on Coronavirus Disease 2019 (COVID-19) Conducted in the National Dental Practice-Based Research Network
  (NOT-DE-20-023)
  National Institute of Dental and Craniofacial Research
  

• RESCINDED - Notice of Special Interest (NOSI): Heart, lung, blood and sleep focused ancillary studies to large ongoing clinical trials
  (NOT-HL-20-755)
  National Heart, Lung, and Blood Institute
  

• Notice of Special Interest (NOSI): Pulmonary Complications of Hematopoietic Stem Cell Transplantation in Childhood
  (NOT-HL-20-761)
  National Heart, Lung, and Blood Institute
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  

• Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions on Coronavirus Disease 2019 (COVID-19) for Currently Active NHLBI Phase I-III Clinical Trials
  (NOT-HL-20-782)
  National Heart, Lung, and Blood Institute
  

• Notice of Special Interest (NOSI): Data Driven Research on Coronavirus Disease 2019 (COVID-19) (R21)
  (NOT-LM-20-011)
  National Library of Medicine
  

• Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System
  (NOT-NS-20-051)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)
  (NOT-RM-20-015)
  Office of Strategic Coordination (Common Fund)
  

Funding Opportunities

• Competitive Revision Supplements to Existing AHRQ Health Service Research (HSR) Grants and Cooperative Agreements to Evaluate Health System and Healthcare Professional Responsiveness to COVID-19 (Supplement - Clinical Trial Optional)
  (PA-20-070)
  Agency for Healthcare Research and Quality
  Application Receipt Date(s): Applications are due by May 29, 2020 by 5:00 PM local time of applicant organization.
  
  

• Competitive Revision Supplements to Existing AHRQ Patient Centered Outcomes Research (PCOR) Grants and Cooperative Agreements to Evaluate Health System and Healthcare Professional Responsiveness to COVID-19 (Supplement - Clinical Trial Optional)
  (PA-20-072)
  Agency for Healthcare Research and Quality
  Application Receipt Date(s): Applications are due by May 29, 2020 by 5:00 PM local time of applicant organization.
  
  

• Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21 Clinical Trial Not Allowed)
  (PAR-20-177)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): Applications will be accepted on a rolling basis, beginning on 04/30/2020 .
  
  

• Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01 Clinical Trial Not Allowed)
  (PAR-20-178)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): Applications will be accepted on a rolling basis, beginning on 04/30/2020 .
  
  

• Advancing Research to Develop Improved Measures and Methods for Understanding Multimorbidity (R01 Clinical Trial Optional)
  (PAR-20-179)
  Office of Disease Prevention
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Institute on Aging
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  Office of Research on Women's Health
  Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is October 05, 2020.
  
  

• Identifying Innovative Mechanisms or Interventions that Target Multimorbidity and Its Consequences (R01 Clinical Trial Optional)
  (PAR-20-180)
  Office of Disease Prevention
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Institute on Aging
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  National Institute of Nursing Research
  Office of Behavioral and Social Sciences Research
  Office of Research on Women's Health
  Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is October 05, 2020.
  
  

• Coordinating Unit to Support the Kidney, Urology and Hematology (KUH) Innovative Science Accelerator Program (ISAC-CU) (U24 Clinical Trial Not Allowed)
  (RFA-DK-20-010)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): August 4, 2020
  
  

• U.S. - India Collaborative Environmental Health Research Program (R01 Clinical Trial Optional)
  (RFA-ES-20-010)
  National Institute of Environmental Health Sciences
  Application Receipt Date(s): October 15, 2020
  
  

• Superfund Research Program Occupational Health and Safety Education Programs on Emerging Technologies (R25 - Clinical Trial Not Allowed)
  (RFA-ES-20-011)
  National Institute of Environmental Health Sciences
  Application Receipt Date(s): August 3, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Limited Competition: Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC) Disease Modifying Therapies for Chronic Lung Diseases (U24 Clinical Trial Required - Infrastructure)
  (RFA-HL-21-012)
  National Heart, Lung, and Blood Institute
  Application Receipt Date(s): July 24, 2020 by 5:00 PM local time of applicant organization.
  
  

• Disease Modifying Therapies for Chronic Lung Disease (R61/R33 Clinical Trial Required)
  (RFA-HL-21-013)
  National Heart, Lung, and Blood Institute
  Application Receipt Date(s): July 24, 2020, March 19, 2021, June 1, 2022. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.